Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.40 |
| ▸ | TEAD1 | P28347 | 2/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.38 |
| ▸ | MAPK3 | P27361 | 6/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17969678 | 1.00 | CSNK2A1 (0.40) | CSNK2A1TEAD1BTKIRAK4PDE7A | |
| SCHEMBL17937489 | 0.86 | CSNK2A1 (0.46) | CSNK2A1IRAK4PDE7APDE7BBRD4 | |
| SCHEMBL16595166 | 0.82 | IRAK4 (0.46) | CSNK2A1IRAK4 | |
| SCHEMBL17937488 | 0.82 | IRAK4 (0.46) | CSNK2A1IRAK4 | |
| SCHEMBL16595369 | 0.80 | BTK (0.44) | CSNK2A1BTKIRAK4PDE7APDE7B | |
| SCHEMBL17937467 | 0.78 | JAK3 (0.49) | BTKIRAK4BRD4JAK3 | |
| SCHEMBL16595362 | 0.78 | JAK3 (0.49) | BTKIRAK4BRD4JAK3 | |
| SCHEMBL17937465 | 0.73 | IRAK4 (0.42) | TEAD1BTKIRAK4MAPK3SMYD3 | |
| SCHEMBL16595542 | 0.73 | JAK3 (0.44) | TEAD1BTKIRAK4MAPK3SMYD3 | |
| SCHEMBL16595154 | 0.73 | IRAK4 (0.42) | TEAD1BTKIRAK4MAPK3SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-04-30 | — | — | US | disclosed |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2019-04-30 | — | — | US | disclosed |
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2018-02-22 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-9840517-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2017-12-12 | — | — | US | disclosed |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-08-11 | — | — | US | disclosed |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-08-11 | — | — | US | disclosed |
| EP-3048105-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | Beijing Hanmi Pharmaceutical Co., Ltd. (CN) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015039612-A1 | COMPOUND INHIBITING KINASE ACTIVITIES OF BTK AND/OR JAK3 | 北京韩美药品有限公司 | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051036-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | BTK, JAK3, JAK2 | CSNK2A1 185/4885TEAD1 2883/4885BTK 1/4885 |
| US-20160229865-A1 | COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES | BTK, JAK3, JAK2 | CSNK2A1 185/4885TEAD1 2883/4885BTK 1/4885 |
| US-10273242-B2 | Compound inhibiting activities of BTK and/or JAK3 kinases | BTK, JAK3, JAK2 | CSNK2A1 185/4885TEAD1 2883/4885BTK 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.